References
- Patte C, Philip T, Rodary C, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol. 1991; 9: 123–132
- Patte C, Auperin A, Michon J, et al. The Société Francaise d’Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97: 3370–3379
- Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage. A report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 1995; 13: 359–372
- Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin–Frankfurt–Munster Group trial NHL BFM 90. Blood 1999; 94: 3294–3306
- Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005; 105: 948–958
- Anderson J R, Jenkin R D, Wilson J F, et al. Long-term follow-up of patients treated with COMP or LSA2-L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Children's Cancer Study Group. J Clin Oncol 1993; 11: 1024–1032
- Muller-Weihrich S, Beck J, Henze G, et al. BFM studie 1981/1983 zur Behandlung hochmaligner Non-Hodgkin-Lymphome bei Kindern: Ergebnisse einer nach histologisch-immunologischem Typ und Ausbreitungsstadium stratifizierten Therapie. Klin Padiatr 1984; 196: 135–142
- Sarialioglu F, Buyukpamukcu M, Akyuz C, Kutluk T. Combined chemotherapy in Non-Burkitt's non-Hodgkin's lymphoma: long term results of a unified protocol. Med Pediatr Oncol. 1993; 21: 532
- Wessels G, Hesseling P B. High dose intense chemotherapy in South African children with B-cell lymphoma: morbidity, supportive measures and outcome. Med Pediatr Oncol 2000; 34: 143–146
- Kavan P, Kabickova E, Gajdos P, et al. Treatment of pediatric B-cell non-Hodgkin's lymphomas at the Motol Hospital in Praque, Czech Republic: results based on the NHL BFM 90 protocols. Pediatr Hematol Oncol 1999; 16: 201–212
- Klumb C E, Schramm M T, De Rense L M, et al. Treatment of children with B-cell non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil. J Pediatr Hematol Oncol. 2004; 26: 462–468
- Acquatella G, Insausti C L, Garcia R, et al. Outcome of children with B cell lymphoma in Venezuela with the LMB-89 protocol. Pediatr Blood Cancer. 2004; 43: 580–586
- Chantada G, Casak S, Alderete D, et al. Treatment of B-cell malignancies in children with a modified BFM-NHL 90 protocol in Argentina. Med Pediatr Oncol 2003; 41: 488–490
- Kutluk T, Varan A, Akyuz C, Buyukpamukcu M. Clinical characteristics and treatment results of LMB/LMT regimen in children with non-Hodgkin's lymphoma. Cancer Invest 2002; 20: 626–633
- Stansfeld A G, Diebold J, Kapanci Y, et al. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292–293
- Murphy S B, Fairclough D L, Hutchinson R E, Berard C W. Non-Hodgkin's lymphoma of childhood: an analysis of the histology, staging and response to treatment of 388 cases at single institution. J Clin Oncol 1989; 7: 186–193
- Buyukpamukcu M. Non-Hodgkin's lymphomas. Cancer in Children, P Voute, C Kalifa, A Barrett. Oxford University Press, Oxford, UK 1998; 119–136
- Link M P, Weinstein H J. Malignant non-Hodgkin lymphomas in children. Principles and Practice of Pediatric Oncology5, P A Pizzo, D G Poplack. Lippincott, Philadelphia 2006; 722–747
- Anderson J R, Wilson J F, Jenkin D T, et al. Childhood non-Hodgkin's lymphoma: the results of a randomized trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 1983; 308: 559–565
- Okur F V, Oguz A, Karadeniz C, et al. Refractoriness to rituximab monotherapy in a child with relapsed/refractory Burkitt non-Hodgkin lymphoma. Pediatr Hematol Oncol. 2006; 23: 25–31
- Ian J C. Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without reducing malignant cell in the central nervous system. Pediatr Hematol Oncol 2004; 26: 156–163